Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Vonicog alfa for Prophylaxis of Haemorrhage in Von Willebrand disease	Vonicog alfa (recombinant von Willebrand factor)	von Willebrand disease	Genetic Disorders , Haematology	2023	View \| Download
Vorasidenib for treating residual or recurrent grade 2 glioma	Vorasidenib	Glioma	Neurological Cancer	2023	View \| Download
Vosoritide for achondroplasia	Vosoritide (BMN 111)	Achondroplasia	Musculoskeletal System	2020	View \| Download
Vosoritide for treating achondroplasia in children	Vosoritide (BMN 111)	Achondroplasia	Musculoskeletal System	2024	View \| Download
Voxelotor for Sickle Cell Disease	Voxelotor (GBT-440)	Sickle cell anaemia	Haematology	2017	View \| Download
Vutrisiran for treating hereditary transthyretin amyloidosis	Vutrisiran (ALN-TTRSC02)	Amyloidosis	Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy	Vutrisiran (ALN-TTRSC02)	Transthyretin amyloid cardiomyopathy	Cardiovascular System	2024	View \| Download
VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 years and older	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
VX-659/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older	Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) , VX-659 (Bamocaftor-potassium)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download